Skip to content
Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)

Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)

Get the podcast

Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with carboplatin in HER-2 positive patients with early breast c

The Audio Journal of Oncology

Dennis Slamon, UCLA School of Medicine, Los AngelesIt may be reasonable to replace the anthracycline component of adjuvant chemotherapy with carboplatin in HER-2 positive patients with early breast cancer – provided agents such as docetaxel and trastuzumab are also included, according to the findings of the BCIRG 006 trial reported at the San Antonio Breast Cancer Symposium.
COMMENT:Norman Wolmark, NSABP foundation, Pittsburg

Click here for all the interviews from San Antonio Breast Cancer Symposium 2005

Tags

chemotherapyfindingspatienttrial

More from SABCS 2005

All 2 interviews

This is the last of the 2 SABCS 2005 interviews. See them all.

Related Episodes

Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers

Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers

“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time i

3 Jul 2025
10 min
Audio Journal of Oncology Volume 16 Number 8

Audio Journal of Oncology Volume 16 Number 8

Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F

15 Apr 2008